title: Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
abstract: Myeloma cast nephropathy contributes to high morbidity and early mortality associated with the development of end-stage renal disease. Treatment with extended high cut-off haemodialysis coupled with novel anti-myeloma therapies enables significant reduction of serum-free light chains and has been shown to improve renal outcomes. In this case series, medical records of 6 patients who received high cut-off haemodialysis for biopsy-proven cast nephropathy were retrospectively reviewed. Patients received a total of 344 hours of high cut-off haemodialysis and concurrent chemotherapy. Only 50% became dialysis independent following treatment. One patient who achieved sustained remission remained dialysis dependent. The added benefit of high cut-off haemodialysis in the light of novel anti-myeloma therapies requires further evaluation.
authors.affiliation: Waitemata District Health Board, Waitemata, New Zealand.
authors.forename: Jasmine
authors.initials: J
authors.lastname: Tan
authors.forename: Michael
authors.initials: M
authors.lastname: Lam-Po-Tang
authors.forename: Colin A
authors.initials: CA
authors.lastname: Hutchison
authors.forename: Janak R
authors.initials: JR
authors.lastname: de Zoysa
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D024221:Antineoplastic Protocols; D001706:Biopsy; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000097:blood; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007668:Kidney / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D007952:Leukemia, Plasma Cell / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D009520:New Zealand; D011719:Pyrazines / Q000008:administration & dosage*; D012074:Remission Induction / Q000379:methods; D006435:Renal Dialysis / Q000379:methods*; D013792:Thalidomide / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D007147:Immunoglobulin Light Chains; D007166:Immunosuppressive Agents; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone
keywords: end-stage kidney disease; free light chains; high cut-off haemodialysis; multiple myeloma